Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status

被引：4

作者：

Tanaka H. ^{[1
]}

Taima K. ^{[1
]}

Morimoto T. ^{[1
]}

Nakamura K. ^{[1
]}

Tanaka Y. ^{[1
]}

Itoga M. ^{[2
]}

Takanashi S. ^{[3
]}

Okumura K. ^{[1
]}

机构：

[1] Department of Cardiology, Respiratory Medicine and Nephrology, Hirosaki University Graduate, School of Medicine, Zaifu-cho 5, Hirosaki

[2] Department of Laboratory Medicine, Hirosaki University, School of Medicine, Honcho 53, Hirosaki

[3] Department of Health Admnistration Center, Hirosaki University, Bunkyo 1, Hirosaki

来源：

BMC Research Notes | / 9卷 / 1期

关键词：

Alectinib; ALK; Lung cancer; Poor performance status;

D O I：

10.1186/s13104-016-1983-9

中图分类号：

学科分类号：

摘要：

Background: Lung cancers with anaplastic lymphoma kinase rearrangements are highly sensitive to anaplastic lymphoma kinase tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to anaplastic lymphoma kinase activity. Several anaplastic lymphoma kinase inhibitors have been identified and are being evaluated in clinical trials. However patients with poor performance status (3 or 4) were not involved in these clinical trials, it has been unclear to use anaplastic lymphoma kinase-tyrosine kinase inhibitors for these patients. Here, we report an anaplastic lymphoma kinase-positive non small cell lung cancer patient with performance status 4, who was successfully treated with alectinib. Case presentation: We report on a 52-year-old patient diagnosed as non small cell lung cancer harboring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. His performance status was 4 because of severe respiratory failure. We treated this patient with alectinib as the first line therapy. Dramatic response was obtained and his performance status improved from 4 to 1 without severe adverse events. Conclusion: Alectinib is a therapeutic option for the anaplastic lymphoma kinase positive patients with poor performance status. © 2016 Tanaka et al.

引用

共 9 条

[1]

Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 20, 368, pp. 2385-2394, (2013)

[2]

Soda M., Choi Y.L., Enomoto M., Takada S., Takada Y., Ishikawa I., Et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, pp. 561-566, (2007)

[3]

Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Et al., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, pp. 1190-1203, (2007)

[4]

Latif M., Saeed A., Kim S.H., Journey of the ALK-inhibitor CH5424802 to phase II clinical trial, Arch Pharm Res, 36, pp. 1051-1054, (2013)

[5]

Yang J.C., A selective ALK inhibitor in ALK-rearranged patients, Lancet Oncol, 14, pp. 564-565, (2013)

[6]

Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., Et al., CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study, Lancet Oncol, 14, pp. 590-598, (2013)

[7]

Tamai K., Nagata K., Otsuka K., Nakagawa A., Tachikawa R., Otsuka K., Et al., Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status, Respir Investig, 51, pp. 46-48, (2013)

[8]

Ahn H.K., Jeon K., Yoo H., Han B., Lee S.J., Park H., Et al., Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer, J Thorac Oncol, 8, pp. 250-253, (2013)

[9]

Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., Et al., First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, 27, pp. 1394-1400, (2009)

← 1 →